This product has not been tested in-house for this application, so a recommendation cannot be provided. Empirical testing based on a literature search may be necessary.
G6423
Gemcitabine hydrochloride
Gemcitabine hydrochloride
1 of 1 reviewers received a sample product or took part in a promotion
≥98% (HPLC), powder, antitumor agent
Synonym(s):
2′-Deoxy-2′,2′-difluorocytidine; dFdC, Gemzar (Lilly), LY-188011, dFdC, dFdCyd
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
Empirical Formula (Hill Notation):
C9H11F2N3O4 · HCl
CAS Number:
Molecular Weight:
299.66
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Pricing and availability is not currently available.
Recommended Products
Product Name
Gemcitabine hydrochloride, ≥98% (HPLC)
Quality Level
Assay
≥98% (HPLC)
form
powder
storage condition
desiccated
protect from light
solubility
H2O: ≥10 mg/mL
originator
Eli Lilly
storage temp.
room temp
SMILES string
Cl.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F
InChI
1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1
InChI key
OKKDEIYWILRZIA-OSZBKLCCSA-N
Gene Information
human ... POLA1(5422) , POLA2(23649) , POLD1(5424) , POLD2(5425) , POLD3(10714) , POLD4(57804) , POLE(5426) , POLE2(5427) , POLE3(54107) , PRIM1(5557) , PRIM2(5558) , RRM1(6240) , RRM2(6241) , RRM2B(50484)
Looking for similar products? Visit Product Comparison Guide
General description
Gemcitabineis a pyrimidine nucleoside analog of deoxycytidine. It exhibits anticancereffects against various cancers.[1]
Application
Gemcitabinehydrochloride has been used as a chemotherapeutic agent to study its effects onthe human pancreatic adenocarcinoma cell line[2]It has been used as a chemotherapeutic to study its resistance inpancreatic stellate cells (PSCs)[3]It has also been used to study its effects on patient-derivedxenograft (PDX) organoids.[4]
Biochem/physiol Actions
Gemcitabine is a widely used antitumor agents in both clinics and research labs. It is an antineoplastic agent and antimetabolite.
Features and Benefits
This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Repr. 1B
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Yuan Chi et al.
Frontiers in oncology, 11, 671082-671082 (2021-12-07)
Pancreatic cancer is associated with poor prognosis and dismal survival rates. This study aims to investigate roles of lncRNA UCA1-loaded exosomes secreted by pancreatic stellate cells (PSCs) in Gemcitabine (Gem) resistance of pancreatic cancer under hypoxia, which involves the methylation
M Barton-Burke
Cancer nursing, 22(2), 176-183 (1999-04-27)
There have been exciting new developments in anticancer therapy over the past few years. One such therapy uses gemcitabine (GemzarR), an antimetabolite approved in 1996 by the Food and Drug Administration (FDA) for first-line treatment of locally advanced (nonresectable stage
Abdullah Shopit et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 91, 153711-153711 (2021-08-28)
Gemcitabine (GCB) is a first-line chemotherapeutic drug for pancreatic cancer (PCa). However, the resistance begins developing within weeks of chemotherapy. SPINK1 overexpression enhances resistance to chemotherapy. In a recent study, our laboratory established that the oleanolic acid (OA) derivative, K73-03
Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors.
Isabel Romero-Calvo et al.
Molecular cancer research : MCR, 17(1), 70-83 (2018-09-02)
Patient-derived pancreatic ductal adenocarcinoma (PDAC) organoid systems show great promise for understanding the biological underpinnings of disease and advancing therapeutic precision medicine. Despite the increased use of organoids, the fidelity of molecular features, genetic heterogeneity, and drug response to the
Erez Hasnis et al.
Neoplasia (New York, N.Y.), 16(6), 501-510 (2014-06-25)
Weekly gemcitabine therapy is the major treatment offered for patients with pancreatic adenocarcinoma cancer; however, relative resistance of tumor cells to chemotherapy, rapid regrowth, and metastasis are the main causes of death within a year. Recently, the daily continuous administration
-
welche maximalen Gemcitabinkonzentrationen werden für in-vitro-Modelle in PDAC-Zelllinien empfohlen? Die Angaben in der Literatur sind teilweise stark voneinander abweichend
1 answer-
Helpful?
-
-
Wie können Aliquotes (in NaCl) am besten gelagert werden? Wäre eine Lagerung bei -20°C bedenkenlos über einen längeren Zeitraum möglich?
1 answer-
This product can be stored in aliquots and frozen at -20°C. Stock solutions are stable for up to 6 months at -20°C.
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
